<?xml version="1.0" encoding="UTF-8"?>
<p>The observed lack of protection in QIV‐immunized ferrets is counterintuitive. However, this finding recapitulated observations by others and likely depended on a failure to induce HAI
 <sup>+</sup> antibodies by the commercial, non‐adjuvanted human vaccine (Baras 
 <italic>et al</italic>, 
 <xref rid="emmm201910938-bib-0010" ref-type="ref">2011</xref>; Nachbagauer 
 <italic>et al</italic>, 
 <xref rid="emmm201910938-bib-0063" ref-type="ref">2017</xref>; Liu 
 <italic>et al</italic>, 
 <xref rid="emmm201910938-bib-0056" ref-type="ref">2019</xref>). Neither in ferrets nor mice, change of the AAV vector capsid was required to achieve high influenza‐specific antibody titers upon intranasal vaccination, even in the presence of AAV9‐neutralizing serum antibodies. This finding is in line with observations by others (Limberis &amp; Wilson, 
 <xref rid="emmm201910938-bib-0052" ref-type="ref">2006</xref>). Seroprevalence of AAV9‐neutralizing antibodies in humans is generally low (Boutin 
 <italic>et al</italic>, 
 <xref rid="emmm201910938-bib-0015" ref-type="ref">2010</xref>), suggesting an advantage over other viral vectors in the context of pre‐existing immunity which critically influences transduction efficiency (Nachbagauer 
 <italic>et al</italic>, 
 <xref rid="emmm201910938-bib-0062" ref-type="ref">2015</xref>; Ryder 
 <italic>et al</italic>, 
 <xref rid="emmm201910938-bib-0073" ref-type="ref">2015</xref>). Current production capacities for AAV vectors allow the production of batches suitable for midscale clinical studies, but recent advances give a perspective that future large‐scale AAV vector production and purification platforms will be able to match the demand for higher number of AAV vector‐based vaccine doses (Nass 
 <italic>et al</italic>, 
 <xref rid="emmm201910938-bib-0064" ref-type="ref">2017</xref>).
</p>
